Ochre Bio appoints Dr. Eliot Forster to its Board of Directors as Chair

– UK, Oxford –  Ochre Bio, an innovator in chronic liver disease medicine development, today announced the appointment of Dr. Eliot Forster (Ph.D.) as Chair of its Board of Directors. With decades of experience in pharmaceutical and biotechnology industries, cofounding and leading several companies Dr. Forster has successfully raised more than $550M in equity financing, having previously served as CEO at F-Star Therapeutics CEO and Immunocore Ltd and Chairperson of Avacta PLC.

About Dr. Eliot Forster

Dr. Eliot Forster has over 30 years of experience in pharmaceuticals and biotechnology. Previously CEO at F-star Therapeutics, Immunocore Ltd, Creabilis Therapeutics, and Solace Pharmaceuticals Inc, he is also non-executive Chairperson of Avacta plc and on the Board of Immatics NV. He is an honorary visiting Professor of Molecular and Clinical Cancer Medicine at the University of Liverpool and an international visiting Professor at the University of Pavia. He is also a Board member of OSCHR (Office for Strategic Coordination of Health Research), and the National Genomics Board.

Eliot holds a B.Sc. in physiology from the University of Liverpool, an MBA from Henley Business School, and a Ph.D. in neurophysiology from the University of Liverpool.

About Ochre Bio

Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases. Using a combination of deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for critical liver health challenges, from increasing donor liver supply to reducing cirrhosis complications.

For more information: https://www.ochre-bio.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.